Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Oct 1 - Oct 6
Hiren Domadiya Address Registered Office: SF 249-250, Aristo, Opp
:max_bytes(150000):strip_icc()/Health-GettyImages-2112991427-c2c4d692054b4ff6933f01fc6c5be06c.jpg)
Although the effect was small and clinically significant, the findings highlight the potential role of genetic variants associated with central adiposity in obesity management
Phase 1b/2a Subcutaneous Formulation (Obesity) Published: The Lancet, June 2025 Participants: 125 adults with overweight or obesity (BMI 27.039.9), aged 1855 Duration: Up to 36 weeks Dosing: Once-weekly subcutaneous amycretin, up to 60 mg Results: - Up to 22% absolute weight loss at 36 weeks (highest dose group) - Placebo-adjusted difference: approximately 24% - No weight-loss plateau observed at study end Safety: 81% of the 89 participants who reported a TEAE had gastrointestinal events
The data presented here demonstrating that reductions in skeletal muscle myostatin mRNA expression improve insulin sensitivity and increased glucose uptake in T1DM mice support this initiative
US$ 25.80
US$ 20.67
US$ 28.45
